Reuters logo
BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors
June 1, 2017 / 11:25 AM / 6 months ago

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

June 1 (Reuters) - Bioline Rx Ltd:

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* Bioline Rx - trials for pancreatic, gastric and non-small cell cancer expected to commence during second half of 2017, after receipt of regulatory approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below